Key facts
- This page summarizes Bryan J. McMichael's Form 4 filing for Coherus Oncology, Inc. (CHRS).
- 12 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2026, 20:31.
Bryan J. McMichael - 29 May 2026 Form 4 Insider Report for Coherus Oncology, Inc. (CHRS)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CHRS
- Reported as of
- 29 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2026, 20:31:37 UTC
- Prior SEC filing
- 26 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bryan McMichael
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Bryan J. McMichael filed Form 4 for Coherus Oncology, Inc. (CHRS) on 02 Jun 2026.
Change
- Previous filing in this sequence was filed on 26 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001944868
Primary reporting owner
McMichael Bryan J
- Relationship
- Chief Financial Officer
- Address
- C/O COHERUS ONCOLOGY, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY
- Signature
- /s/ Bryan McMichael
- Signature date
- 02 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $14.76
- Footnotes
- F1, F5
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $14.67
- Footnotes
- F1, F5
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $10.78
- Footnotes
- F2, F5
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $9.87
- Footnotes
- F3, F5
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $6.00
- Footnotes
- F4, F5
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -30,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $5.44
- Footnotes
- F1, F5
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +100,000
- Change %
- Price
- Shares after
- 100,000
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.59
- Footnotes
- F1, F5, F6
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.59
- Footnotes
- F1, F5, F6
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +15,000
- Change %
- Price
- Shares after
- 15,000
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $1.59
- Footnotes
- F2, F5, F6
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.59
- Footnotes
- F3, F5, F6
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.59
- Footnotes
- F4, F5, F6
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +30,000
- Change %
- Price
- Shares after
- 30,000
- Date
- 29 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $1.59
- Footnotes
- F1, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The option is fully vested and exercisable.
Footnote F2
The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from September 7, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Footnote F3
The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Footnote F4
The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 27, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Footnote F5
On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.
Footnote F6
On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.